Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Triple drug cocktail targets tough pancreatic cancer

NCT ID NCT01204372

Disease control Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 study tested a combination of three drugs—gemcitabine, trastuzumab, and erlotinib—as a first treatment for people with metastatic pancreatic cancer that has spread. The goal was to see if the combination could control tumor growth. 63 patients received the drugs intravenously and orally until their disease worsened or side effects became too severe. The study measured how well the tumors shrank or stabilized, and how long patients lived without the cancer growing.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Gemcitabine, Trastuzumab, and Erlotinib
What this could lead to
If successful, this combination could offer a new first-line treatment option to help control metastatic pancreatic cancer and extend survival.
What could go wrong
This is a small, early-phase trial with no comparison group, so results may not be definitive. The drugs can cause significant side effects, and the cancer may still progress.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

63 people

The number who actually took part.

Started

Jun 2010

Finished

Aug 2016

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Metastatic pancreatic adenocarcinoma confirmed by histology * Tumor sample available * Measurable lesion according to RECIST criteria * Performance status ≥ 1 * Life expectancy \> 3 months * Hematology: Hb ≥ 9g/dL, neutrophils ≥ 1,500/mm3, platelets ≥ 100,000/mm3 * Renal function: creatinine ≤ 1.5 x ULN * Hepatic function: total bilirubin ≤ 2.5 x ULN, transaminases ≤ 5 x ULN * Left ventricular ejection fraction (LVEF) ≥ 50% * At least a 6-month delay between the end of any previous gemcitabine-based chemotherapy and diagnosis of metastases * Social security * Informed consent obtained prior to inclusion. Exclusion Criteria: * Non metastatic advanced local disease * Presence of cerebral metastases or symptomatic leptomeningeal carcinomatosis * Others cancers except BBC and cervical cancer receiving curative treatment * No previous treatment by Erlotinib or Trastuzumab * Known severe hypersensitivity to Erlotinib, Trastuzumab, murine proteins or Gemcitabine * Presence of significant co-morbidities * Concomitant treatment with other experimental products or other anticancer therapies * Breastfeeding or pregnant female, or patient of reproductive age not using adequate contraception * Legal incapacity or limited legal incapacity

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic pancreatic adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

pancreatic adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metastatic pancreatic adenocarcinoma

Contacts and locations

Locations

  • Centre Val d'Aurelle

    Montpellier, 34298, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.